Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora
NCT ID: NCT04088474
Last Updated: 2019-09-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
36 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-03-05
Study Completion Date
2016-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This clinical trial was conducted as part of the "Methods for Evaluating the Improvement of Gastrointestinal Function in Health Food" announced by the Department of Health, DOH (currently known as Ministry of Health and Welfare, MOHW) on the test article, "Vigiis 101-LAB powder (Capsules)", manufactured by SunWay Biotech Co., Ltd.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity
NCT04046432
Gastrointestinal Microbiome
COMPLETED
NA
Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication
NCT03722433
Helicobacter Pylori Infection
UNKNOWN
PHASE4
Research on the Improvement of Intestinal and Immune Functions by Probiotics
NCT06873425
Intestinal Health
NOT_YET_RECRUITING
NA
The Impact of Compound Probiotic Freeze-dried Powder on Enhancing Gastrointestinal Health
NCT07025798
Gastrointestinal Tract
COMPLETED
NA
Research on the Role of Probiotics in Human Intestinal Health
NCT06886711
Intestinal Microbiota
NOT_YET_RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1.1 Introduction The human microbiome comprises diverse microbiologic ecosystems and is composed of a variety of bacteria, archaea, microeukaryotes, and viruses. Although investigators have appreciated the diversity of our microbial world for decades, scientists were constrained by the inability to culture many bacteria in the laboratory. Paradigms in biomedical science and medicine are changing in a fundamental way as investigators explore potential contributions of human-associated microbes to health and expand our understanding of disease susceptibility and pathogenesis. In the 21st century, investigators are attempting to develop a more balanced mindset as investigators seek to understand the role of the human microbiome in physiology and manipulate it to optimize health and prevent or treat disease. In recent years, investigators have increased our understanding of microbial communities and their corresponding metagenomes at different human body sites greatly. Healthy gastrointestinal (GI) microbiome should include age, sex, race/ethnicity, and diet. The Human Microbiome Project documented the importance of considering sex and race/ethnicity in evaluating differences between microbiomes of individuals. The human GI microbiome comprises diverse microbial communities that differ based on their location along the length of the GI tract (esophagus, stomach, small intestine, and large intestine or colon). Most human intestinal microbiome studies have relied on stool specimens. Probiotics have showed to possess anti mutagenic, anti carcinogenic and hypocholesterolemic properties. It is well-known that probiotics have a number of beneficial health effects in humans and animals, including the reduction of symptoms in lactose intolerance and enhancement of the bio availability of nutrients. Further, they were also observed to have antagonistic actions against intestinal and food-borne pathogens, to decrease the prevalence of allergies in susceptible individuals and to have immunomodulatory effects. Typically, the bacteria colonise the intestinal tract first and then reinforce the host defence systems by inducing a generalised mucosal immune response, balanced T-helper cell response, self-limited inflammatory response and secretion of polymeric IgA. Scientific reports showed that the Taiwan native lactic acid bacterium from newborn infant faeces identified as Lactobacillus paracasei subsp. paracasei NTU 101 and its fermented products proved to be effective for the management of blood cholesterol and pressure, prevention of gastric mucosal lesion development, immunomodulation and alleviation of allergies, anti-osteoporosis and inhibition the fat tissue accumulation.
1.2 Materials The strain used in the current study was L. paracasei subsp. paracasei NTU 101 (lyophilized powdered, Vigiis 101-LAB; probiotic powder from SunWay Biotech Co., Ltd., Taipei, Taiwan). The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule) containing 5 billion bacteria per capsule for the gut flora clinical trial. Maltodextrin was used as a placebo.
1.3 Randomized, double-blind clinical criteria of effects of Vigiis 101-LAB capsule I on gut flora (clinical trial) Vigiis 101-LAB capsule was administered orally once per day, one capsule each time. The entire study took 4 weeks, and subjects were prohibited from eating fermented food products, such as miso, kimchi, fermented dairy products, oligosaccharide-containing foods, and lactic acid bacteria-containing products. Subjects also avoided consuming excessive gas-producing foods (such as soybeans and sweet potatoes) during their daily meals and avoided foods that can cause abdominal distension or promote peristalsis (such as lactic acid beverages and oligosaccharide-containing beverages). After the trial started, subjects recorded their daily number of bowel movements and completed relevant questionnaires at weeks 0, 2, and 4. The subjects visited the doctor once every 2 weeks for monitoring gastrointestinal function and physiological characteristics. At weeks 0, 1, 2, 3, and 4, fecal samples from the subjects were collected and put into bottles containing an anaerobic diluent and shaken to uniformly mix the feces and diluent.
1.4 Outcome measurements Fecal moisture content and pH value testing. Blood biochemical tests were carried out in the laboratory.
1.5. Statistical analysis Data are expressed as the mean ± standard deviation (SD). The statistical significance of the biochemical analyses was determined by one-way analysis of variance (ANOVA) using the general linear model procedure of the statistical product and service solutions software (SPSS Institute, Inc., Chicago, IL, USA). This was followed by ANOVA with a paired t-test to evaluate the difference before and after sample and placebo administration, while the Student t-test was used to compare the difference between test and placebo groups (P ≤ 0.05).
1.2 Materials The strain used in the current study was L. paracasei subsp. paracasei NTU 101 (lyophilized powdered, Vigiis 101-LAB; probiotic powder from SunWay Biotech Co., Ltd., Taipei, Taiwan). The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule) containing 5 billion bacteria per capsule for the gut flora clinical trial. Maltodextrin was used as a placebo.
1.3 Randomized, double-blind clinical criteria of effects of Vigiis 101-LAB capsule I on gut flora (clinical trial) Vigiis 101-LAB capsule was administered orally once per day, one capsule each time. The entire study took 4 weeks, and subjects were prohibited from eating fermented food products, such as miso, kimchi, fermented dairy products, oligosaccharide-containing foods, and lactic acid bacteria-containing products. Subjects also avoided consuming excessive gas-producing foods (such as soybeans and sweet potatoes) during their daily meals and avoided foods that can cause abdominal distension or promote peristalsis (such as lactic acid beverages and oligosaccharide-containing beverages). After the trial started, subjects recorded their daily number of bowel movements and completed relevant questionnaires at weeks 0, 2, and 4. The subjects visited the doctor once every 2 weeks for monitoring gastrointestinal function and physiological characteristics. At weeks 0, 1, 2, 3, and 4, fecal samples from the subjects were collected and put into bottles containing an anaerobic diluent and shaken to uniformly mix the feces and diluent.
1.4 Outcome measurements Fecal moisture content and pH value testing. Blood biochemical tests were carried out in the laboratory.
1.5. Statistical analysis Data are expressed as the mean ± standard deviation (SD). The statistical significance of the biochemical analyses was determined by one-way analysis of variance (ANOVA) using the general linear model procedure of the statistical product and service solutions software (SPSS Institute, Inc., Chicago, IL, USA). This was followed by ANOVA with a paired t-test to evaluate the difference before and after sample and placebo administration, while the Student t-test was used to compare the difference between test and placebo groups (P ≤ 0.05).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Gastrointestinal Microbiome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
FACTORIAL
a randomized, double-blind, placebo-controlled clinical study
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
SINGLE
Participants
a randomized, double-blind, placebo-controlled clinical study
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vigiis 101-LAB
The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.
Group Type
EXPERIMENTAL
Vigiis 101-LAB
Intervention Type
DIETARY_SUPPLEMENT
examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
placebo
Maltodextrin was used as a placebo.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Maltodextrin was used as a placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vigiis 101-LAB
examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Maltodextrin was used as a placebo
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Healthy adults aged ≧ 20 years and ≦ 65 years.
2. Subjects with normal weight (body mass index: 18.5-24).
3. Subjects with no gastrointestinal diseases or on medication.
2. Subjects with normal weight (body mass index: 18.5-24).
3. Subjects with no gastrointestinal diseases or on medication.
Exclusion Criteria
1. Pregnant or lactating women.
2. Subjects who are allergic to Lactobacillus.
3. Subjects with chronic gastrointestinal diseases.
4. Subjects who previously underwent gastrectomy or gastric bypass.
5. Subjects with liver, kidney, or heart disease, alcoholism, or uncontrolled diabetes.
6. Subjects who developed stroke, psychiatric diseases, or depression within the last 1 year.
7. Subjects being administered drugs that can regulate gastrointestinal function, functional foods, bacteriostatic drugs or supplements, antibiotics, antioxidants, or other unknown drugs within the last 2 weeks.
2. Subjects who are allergic to Lactobacillus.
3. Subjects with chronic gastrointestinal diseases.
4. Subjects who previously underwent gastrectomy or gastric bypass.
5. Subjects with liver, kidney, or heart disease, alcoholism, or uncontrolled diabetes.
6. Subjects who developed stroke, psychiatric diseases, or depression within the last 1 year.
7. Subjects being administered drugs that can regulate gastrointestinal function, functional foods, bacteriostatic drugs or supplements, antibiotics, antioxidants, or other unknown drugs within the last 2 weeks.
Minimum Eligible Age
20 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SunWay Biotech Co., LTD.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jyh Ming Liou, MD,PHD
Role: STUDY_DIRECTOR
National Taiwan University Hospital
Tsong Ming Lu, MD
Role: PRINCIPAL_INVESTIGATOR
Cheng Hsin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine
Taipei, , Taiwan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
References
Explore related publications, articles, or registry entries linked to this study.
Agace WW, McCoy KD. Regionalized Development and Maintenance of the Intestinal Adaptive Immune Landscape. Immunity. 2017 Apr 18;46(4):532-548. doi: 10.1016/j.immuni.2017.04.004.
Reference Type
RESULT
Arnao MB, Cano A, Hernandez-Ruiz J, Garcia-Canovas F, Acosta M. Inhibition by L-ascorbic acid and other antioxidants of the 2.2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) oxidation catalyzed by peroxidase: a new approach for determining total antioxidant status of foods. Anal Biochem. 1996 May 1;236(2):255-61. doi: 10.1006/abio.1996.0164.
Reference Type
RESULT
Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011 Jan 21;331(6015):337-41. doi: 10.1126/science.1198469. Epub 2010 Dec 23.
Reference Type
RESULT
Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27;157(1):121-41. doi: 10.1016/j.cell.2014.03.011.
Reference Type
RESULT
Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. Immunity. 2017 Apr 18;46(4):562-576. doi: 10.1016/j.immuni.2017.04.008.
Reference Type
RESULT
Bengmark S. Gut microbiota, immune development and function. Pharmacol Res. 2013 Mar;69(1):87-113. doi: 10.1016/j.phrs.2012.09.002. Epub 2012 Sep 16.
Reference Type
RESULT
Bridgman SL, Azad MB, Field CJ, Haqq AM, Becker AB, Mandhane PJ, Subbarao P, Turvey SE, Sears MR, Scott JA, Wishart DS, Kozyrskyj AL; CHILD Study Investigators. Fecal Short-Chain Fatty Acid Variations by Breastfeeding Status in Infants at 4 Months: Differences in Relative versus Absolute Concentrations. Front Nutr. 2017 Apr 10;4:11. doi: 10.3389/fnut.2017.00011. eCollection 2017.
Reference Type
RESULT
Chen T, Isomaki P, Rimpilainen M, Toivanen P. Human cytokine responses induced by gram-positive cell walls of normal intestinal microbiota. Clin Exp Immunol. 1999 Nov;118(2):261-7. doi: 10.1046/j.1365-2249.1999.01047.x.
Reference Type
RESULT
Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc. 2001 Feb;101(2):229-38; quiz 239-41. doi: 10.1016/S0002-8223(01)00060-8.
Reference Type
RESULT
Krasowska A, Sigler K. How microorganisms use hydrophobicity and what does this mean for human needs? Front Cell Infect Microbiol. 2014 Aug 19;4:112. doi: 10.3389/fcimb.2014.00112. eCollection 2014.
Reference Type
RESULT
Lee N, Kim WU. Microbiota in T-cell homeostasis and inflammatory diseases. Exp Mol Med. 2017 May 26;49(5):e340. doi: 10.1038/emm.2017.36.
Reference Type
RESULT
Dement JM, Epling C, Joyner J, Cavanaugh K. Impacts of Workplace Health Promotion and Wellness Programs on Health Care Utilization and Costs: Results From an Academic Workplace. J Occup Environ Med. 2015 Nov;57(11):1159-69. doi: 10.1097/JOM.0000000000000555.
Reference Type
RESULT
Lin FM, Chiu CH, Pan TM. Fermentation of a milk-soymilk and Lycium chinense Miller mixture using a new isolate of Lactobacillus paracasei subsp. paracasei NTU101 and Bifidobacterium longum. J Ind Microbiol Biotechnol. 2004 Dec;31(12):559-64. doi: 10.1007/s10295-004-0184-z. Epub 2004 Nov 18.
Reference Type
RESULT
Liu CF, Tung YT, Wu CL, Lee BH, Hsu WH, Pan TM. Antihypertensive effects of Lactobacillus-fermented milk orally administered to spontaneously hypertensive rats. J Agric Food Chem. 2011 May 11;59(9):4537-43. doi: 10.1021/jf104985v. Epub 2011 Apr 4.
Reference Type
RESULT
Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010 Jul;4(8):118-26. doi: 10.4103/0973-7847.70902.
Reference Type
RESULT
Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA. Antioxidant activities of carotenes and xanthophylls. FEBS Lett. 1996 Apr 22;384(3):240-2. doi: 10.1016/0014-5793(96)00323-7.
Reference Type
RESULT
Naidu AS, Bidlack WR, Clemens RA. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr. 1999 Jan;39(1):13-126. doi: 10.1080/10408699991279187.
Reference Type
RESULT
Orrhage K, Sillerstrom E, Gustafsson JA, Nord CE, Rafter J. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Mutat Res. 1994 Dec 1;311(2):239-48. doi: 10.1016/0027-5107(94)90182-1.
Reference Type
RESULT
Ouwehand AC, Isolauri E, Kirjavainen PV, Tolkko S, Salminen SJ. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol. 2000 Jan;30(1):10-3. doi: 10.1046/j.1472-765x.2000.00590.x.
Reference Type
RESULT
Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek. 2002 Aug;82(1-4):279-89.
Reference Type
RESULT
Pant N, Marcotte H, Brussow H, Svensson L, Hammarstrom L. Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol. 2007 Sep 27;7:86. doi: 10.1186/1471-2180-7-86.
Reference Type
RESULT
Perdigon G, Vintini E, Alvarez S, Medina M, Medici M. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J Dairy Sci. 1999 Jun;82(6):1108-14. doi: 10.3168/jds.S0022-0302(99)75333-6.
Reference Type
RESULT
Pool-Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, Rumney C, Moretti M, Vilarini I, Scassellati-Sforzolini R, Rowland I. Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer. 1996;26(3):365-80. doi: 10.1080/01635589609514492.
Reference Type
RESULT
Rafter J. The effects of probiotics on colon cancer development. Nutr Res Rev. 2004 Dec;17(2):277-84. doi: 10.1079/NRR200484.
Reference Type
RESULT
Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994 Oct 15;344(8929):1046-9. doi: 10.1016/s0140-6736(94)91708-6.
Reference Type
RESULT
Sekine K, Toida T, Saito M, Kuboyama M, Kawashima T, Hashimoto Y. A new morphologically characterized cell wall preparation (whole peptidoglycan) from Bifidobacterium infantis with a higher efficacy on the regression of an established tumor in mice. Cancer Res. 1985 Mar;45(3):1300-7.
Reference Type
RESULT
Sheng Y, Yang X, Lian Y, Zhang B, He X, Xu W, Huang K. Characterization of a cadmium resistance Lactococcus lactis subsp. lactis strain by antioxidant assays and proteome profiles methods. Environ Toxicol Pharmacol. 2016 Sep;46:286-291. doi: 10.1016/j.etap.2016.08.008. Epub 2016 Aug 6.
Reference Type
RESULT
Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013 Aug 2;341(6145):569-73. doi: 10.1126/science.1241165. Epub 2013 Jul 4.
Reference Type
RESULT
Stecher B. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection. Microbiol Spectr. 2015 Jun;3(3). doi: 10.1128/microbiolspec.MBP-0008-2014.
Reference Type
RESULT
Sun Y, O'Riordan MX. Regulation of bacterial pathogenesis by intestinal short-chain Fatty acids. Adv Appl Microbiol. 2013;85:93-118. doi: 10.1016/B978-0-12-407672-3.00003-4.
Reference Type
RESULT
Tomkovich S, Jobin C. Microbiota and host immune responses: a love-hate relationship. Immunology. 2016 Jan;147(1):1-10. doi: 10.1111/imm.12538. Epub 2015 Nov 2.
Reference Type
RESULT
Tsai TY, Chu LH, Lee CL, Pan TM. Atherosclerosis-preventing activity of lactic acid bacteria-fermented milk-soymilk supplemented with Momordica charantia. J Agric Food Chem. 2009 Mar 11;57(5):2065-71. doi: 10.1021/jf802936c.
Reference Type
RESULT
Tsai YT, Cheng PC, Fan CK, Pan TM. Time-dependent persistence of enhanced immune response by a potential probiotic strain Lactobacillus paracasei subsp. paracasei NTU 101. Int J Food Microbiol. 2008 Dec 10;128(2):219-25. doi: 10.1016/j.ijfoodmicro.2008.08.009. Epub 2008 Aug 26.
Reference Type
RESULT
Tuson HH, Weibel DB. Bacteria-surface interactions. Soft Matter. 2013 May 14;9(18):4368-4380. doi: 10.1039/C3SM27705D.
Reference Type
RESULT
Van de Water J, Keen CL, Gershwin ME. The influence of chronic yogurt consumption on immunity. J Nutr. 1999 Jul;129(7 Suppl):1492S-5S. doi: 10.1093/jn/129.7.1492S.
Reference Type
RESULT
Yu X, Li S, Yang D, Qiu L, Wu Y, Wang D, Shah NP, Xu F, Wei H. A novel strain of Lactobacillus mucosae isolated from a Gaotian villager improves in vitro and in vivo antioxidant as well as biological properties in D-galactose-induced aging mice. J Dairy Sci. 2016 Feb;99(2):903-914. doi: 10.3168/jds.2015-10265. Epub 2015 Dec 17.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sunway002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Probiotics and Non-Organic Gastrointestinal Improvement
NCT07081100
RECRUITING
NA
Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers
NCT05083572
UNKNOWN
PHASE4
Investigating the Efficacy of Probiotics in Enhancing Gastrointestinal and Immunological Health
NCT06886724
NOT_YET_RECRUITING
NA
Research on the Role of Compound Probiotic Freeze-dried Powder in Improving Gastrointestinal Function
NCT06781814
COMPLETED
NA
Study on the Enhancement of Intestinal and Immune Functions Through Probiotic Intervention
NCT06863415
NOT_YET_RECRUITING
NA
Efficacy Assessment of Probiotics Product on Intestinal Health and Immune System Improvement
NCT04903600
UNKNOWN
NA
Development and Evaluation of Functional Probiotic Powder in Human Trials
NCT06760468
NOT_YET_RECRUITING
NA
Effect of Probiotic on the Gut Microbiota of Healthy Volunteers
NCT06103253
COMPLETED
NA
Effect of GOS Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults
NCT01848535
COMPLETED
NA
The Role of Probiotic LH76 in Human Gut Health
NCT06875375
NOT_YET_RECRUITING
NA
Probiotics to Promote Intestinal Health
NCT02046512
COMPLETED
PHASE4
The Effect of Probiotics on the Improvement of Intestinal and Immune Function
NCT06873438
COMPLETED
NA
Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults
NCT01143623
COMPLETED
PHASE2/PHASE3
Prospective Tolerability Assessment of a Probiotic Dietary Supplement
NCT04044144
COMPLETED
NA
The Effect of Probiotics on the Improvement of Digestive Function and Well-being in the Elderly
NCT06648590
COMPLETED
NA
Evaluation of the Effect of Changyou Probiotic Flavored Yogurt on Intestinal Health
NCT04375475
COMPLETED
NA
Effect of Bifidobacterium Animalis Subsp. Lactis Bi66 Supplementation on Gut Function in Healthy Adults
NCT06740500
NOT_YET_RECRUITING
NA
Immune System Stimulation by Probiotic Food Supplementation
NCT03049579
COMPLETED
NA
Efficacy and Safety of Probiotic Products for Digestive Health
NCT06385639
RECRUITING
NA
Probiotics Improve Health Young Volunteers' Gut Microbiota
NCT06196892
COMPLETED
NA
Effect of Probiotics on Regulating Gut Health and Blood Lipid in Adults
NCT06554314
RECRUITING
NA
The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms
NCT05845073
COMPLETED
NA
Effects of Fermented Dairy Products on Defecation Changes Through Gut Microbiota
NCT06862310
COMPLETED
NA
Impact of a Synbiotic Containing Fructo-oligosaccharides and Bifidobacteria in Middle-aged Adults
NCT04283266
COMPLETED
NA
Maternal Probiotic Intervention to Improve Gut Health
NCT06196450
RECRUITING
PHASE2